Deferasirox Versus Deferoxamine in Managing Iron Overload in Patients with Sickle Cell Anaemia: a Systematic Review and Meta-analysis

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2022 Dec 23

PMID 36562113

Authors

Talal Qadah

Affiliations

Soon will be listed here.

Abstract

Objectives: To examine the efficacy of deferasirox (DFX) by comparison with deferoxamine (DFO) in managing iron overload in patients with sickle cell anaemia (SCA).

Methods: Online databases were systematically searched for studies published from January 2007 to July 2022 that had investigated the efficacy of DFX compared with DFO in managing iron overload in patients with SCA.

Results: Of the 316 articles identified, three randomized clinical trials met the inclusion criteria. Meta-analysis of liver tissue iron concentration (LIC) showed that iron overload was not significantly higher in the DFX group compared with DFO group (WMD, -1.61 mg Fe/g dw (95% CI -4.42 to 1.21). However, iron overload as measured by serum ferritin was significantly lower in DFO compared with DFX group (WMD, 278.13 µg/l (95% CI 36.69 to 519.57). Although meta-analysis was not performed on myocardial iron concentration due to incomplete data, the original report found no significant difference between DFX and DFO.

Conclusion: While limited by the number of studies included in this meta-analysis, overall, the results tend to show that DFX was as effective as DFO in managing iron overload in patients with SCA.

Citing Articles

Fracture Fusion on Fast-Forward: Locally Administered Deferoxamine Significantly Enhances Fracture Healing in Animal Models: A Systematic Review and Meta-Analysis.

Muller D, Klotsche J, Kosik M, Perka C, Buttgereit F, Hoff P Adv Sci (Weinh). 2025; 12(8):e2413290.

PMID: 39840407 PMC: 11848589. DOI: 10.1002/advs.202413290.

Ultrasound targeted microbubble destruction assisted exosomal delivery of siHmox1 effectively inhibits doxorubicin-induced cardiomyocyte ferroptosis.

Chen J, Qiu S, Liu Y, Sun W, Zhou T, Zhao L J Nanobiotechnology. 2024; 22(1):531.

PMID: 39218878 PMC: 11367924. DOI: 10.1186/s12951-024-02794-w.

References

Dou H, Qin Y, Chen G, Zhao Y . Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis. Acta Haematol. 2018; 141(1):32-42. DOI: 10.1159/000494487. View

Kuo K, Mrkobrada M . A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Hemoglobin. 2014; 38(6):409-21. DOI: 10.3109/03630269.2014.965781. View

Guyatt G, Oxman A, Kunz R, Woodcock J, Brozek J, Helfand M . GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011; 64(12):1294-302. DOI: 10.1016/j.jclinepi.2011.03.017. View

Vichinsky E, Torres M, Minniti C, Barrette S, Habr D, Zhang Y . Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013; 88(12):1068-73. DOI: 10.1002/ajh.23569. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Inusa B, Hsu L, Kohli N, Patel A, Ominu-Evbota K, Anie K . Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment. Int J Neonatal Screen. 2020; 5(2):20. PMC: 7510211. DOI: 10.3390/ijns5020020. View

Locke M, Reddy P, Badawy S . Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review. Hemoglobin. 2022; 46(4):201-213. PMC: 9948767. DOI: 10.1080/03630269.2022.2072320. View

Calvaruso G, Vitrano A, Di Maggio R, Ballas S, Steinberg M, Rigano P . Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells Mol Dis. 2014; 53(4):265-71. DOI: 10.1016/j.bcmd.2014.04.004. View

Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A . Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011; 47(3):166-75. DOI: 10.1016/j.bcmd.2011.07.002. View

10.

Li J, Lin Y, Li X, Zhang J . Economic Evaluation of Chelation Regimens for β-Thalassemia Major: a Systematic Review. Mediterr J Hematol Infect Dis. 2019; 11(1):e2019036. PMC: 6613630. DOI: 10.4084/MJHID.2019.036. View

11.

Li J, Wang P, Li X, Wang Q, Zhang J, Lin Y . Cost-Utility Analysis of four Chelation Regimens for β-thalassemia Major: a Chinese Perspective. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020029. PMC: 7202351. DOI: 10.4084/MJHID.2020.029. View

12.

Pennell D, Porter J, Piga A, Lai Y, El-Beshlawy A, Belhoul K . A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014; 123(10):1447-54. PMC: 3945858. DOI: 10.1182/blood-2013-04-497842. View

13.

Miller A, Gladwin M . Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med. 2012; 185(11):1154-65. PMC: 3373067. DOI: 10.1164/rccm.201111-2082CI. View

14.

Fortin P, Fisher S, Madgwick K, Trivella M, Hopewell S, Doree C . Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database Syst Rev. 2018; 5:CD012349. PMC: 5985157. DOI: 10.1002/14651858.CD012349.pub2. View

15.

Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P . A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007; 136(3):501-8. PMC: 1974786. DOI: 10.1111/j.1365-2141.2006.06455.x. View

16.

Ballas S, Zeidan A, Duong V, DeVeaux M, Heeney M . The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review. Am J Hematol. 2018; 93(7):943-952. DOI: 10.1002/ajh.25103. View

17.

Sridharan K, Sivaramakrishnan G . Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Rev Clin Pharmacol. 2018; 11(6):641-650. DOI: 10.1080/17512433.2018.1473760. View

18.

Serjeant G, Vichinsky E . Variability of homozygous sickle cell disease: The role of alpha and beta globin chain variation and other factors. Blood Cells Mol Dis. 2017; 70:66-77. DOI: 10.1016/j.bcmd.2017.06.004. View

19.

Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M . Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol. 2020; 7(6):e469-e478. DOI: 10.1016/S2352-3026(20)30100-9. View

20.

Cheng W, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P . Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets. Curr Med Res Opin. 2018; 34(11):1959-1966. DOI: 10.1080/03007995.2018.1470500. View